lum001
Progressive Familial Intrahepatic Cholestasis
Mirum Pharmaceuticals, Inc.Phase 2Active
B
62/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 47/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Progressive Familial Intrahepatic Cholestasis cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
ODEVIXIBAT Albireo | Phase 1 | CCC |
Questran Albireo | Phase 1 | CC |
Cholestyramine Albireo | Phase 1 | CC |
[14c]-a4250 Albireo | Phase 1 | CC |
lum001 Mirum Pharmaceuticals, Inc. | Phase 2 | NR |
Same molecule, other indications
lum001 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →